These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14582122)

  • 1. Invesgations [correction investigations] on the influence of halide substituents on the estrogen receptor interaction of 2, 4, 5-tris(4-hydroxyphenyl)imidazoles.
    Gust R; Busch S; Keilitz R; Schmidt K; Von Rauch M
    Arch Pharm (Weinheim); 2003 Oct; 336(10):456-65. PubMed ID: 14582122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
    Lubczyk V; Bachmann H; Gust R
    J Med Chem; 2003 Apr; 46(8):1484-91. PubMed ID: 12672249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, structural evaluation, and estrogen receptor interaction of 4,5-bis(4-hydroxyphenyl)imidazoles.
    Gust R; Keilitz R; Schmidt K; von Rauch M
    Arch Pharm (Weinheim); 2002 Dec; 335(10):463-71. PubMed ID: 12506394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of C2-alkylation, N-alkylation, and N,N'-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
    von Rauch M; Schlenk M; Gust R
    J Med Chem; 2004 Feb; 47(4):915-27. PubMed ID: 14761193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic/anti-estrogenic properties.
    Gust R; Lubczyk V
    J Steroid Biochem Mol Biol; 2003 Jul; 86(1):57-70. PubMed ID: 12943745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
    von Rauch M; Busch S; Gust R
    J Med Chem; 2005 Jan; 48(2):466-74. PubMed ID: 15658860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
    Lubczyk V; Bachmann H; Gust R
    J Med Chem; 2002 Nov; 45(24):5358-64. PubMed ID: 12431063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles.
    Wiglenda T; Gust R
    J Med Chem; 2007 Apr; 50(7):1475-84. PubMed ID: 17352461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode.
    Gust R; Keilitz R; Schmidt K; von Rauch M
    J Med Chem; 2002 Aug; 45(16):3356-65. PubMed ID: 12139447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations of new lead structures for the design of selective estrogen receptor modulators.
    Gust R; Keilitz R; Schmidt K
    J Med Chem; 2001 Jun; 44(12):1963-70. PubMed ID: 11384241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and pharmacological evaluation of 1H-imidazoles as ligands for the estrogen receptor and cytotoxic inhibitors of the cyclooxygenase.
    Wiglenda T; Ott I; Kircher B; Schumacher P; Schuster D; Langer T; Gust R
    J Med Chem; 2005 Oct; 48(20):6516-21. PubMed ID: 16190777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines.
    Gust R; Keilitz R; Schmidt K
    J Med Chem; 2002 May; 45(11):2325-37. PubMed ID: 12014971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.
    Schertl S; Hartmann RW; Batzl-Hartmann C; Schlemmer R; Spruss T; Bernhardt G; Gust R; Schönenberger H
    Arch Pharm (Weinheim); 2001 Apr; 334(4):125-37. PubMed ID: 11382148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.
    Jacquot Y; Laïos I; Cleeren A; Nonclercq D; Bermont L; Refouvelet B; Boubekeur K; Xicluna A; Leclercq G; Laurent G
    Bioorg Med Chem; 2007 Mar; 15(6):2269-82. PubMed ID: 17275315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
    J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents.
    Liu W; Bensdorf K; Proetto M; Abram U; Hagenbach A; Gust R
    J Med Chem; 2011 Dec; 54(24):8605-15. PubMed ID: 22091836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha.
    Zimmermann J; Liebl R; von Angerer E
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):57-66. PubMed ID: 15862950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of 17alpha-20E-21-(4-substituted phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diols as probes for the estrogen receptor alpha hormone binding domain.
    Hanson RN; Lee CY; Friel CJ; Dilis R; Hughes A; DeSombre ER
    J Med Chem; 2003 Jul; 46(14):2865-76. PubMed ID: 12825929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.